Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D. Braunschmid T, et al. Among authors: kuhrer i. Ann N Y Acad Sci. 2018 Dec;1434(1):46-53. doi: 10.1111/nyas.13947. Epub 2018 Aug 15. Ann N Y Acad Sci. 2018. PMID: 30112858 Free article. Review.
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D, Schoppmann SF, Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kührer I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J. Kandioler D, et al. Among authors: kuhrer i. J Thorac Cardiovasc Surg. 2014 Nov;148(5):2280-6. doi: 10.1016/j.jtcvs.2014.06.079. Epub 2014 Jul 22. J Thorac Cardiovasc Surg. 2014. PMID: 25135238 Free article. Clinical Trial.
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG). Kandioler D, et al. Among authors: kuhrer i. EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug. EBioMedicine. 2015. PMID: 26425688 Free PMC article. Clinical Trial.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: kuhrer i. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W. Kandioler D, et al. Among authors: kuhrer i. J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41. doi: 10.1016/j.jtcvs.2007.10.072. J Thorac Cardiovasc Surg. 2008. PMID: 18455581 Free article.
TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.
Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F. Kandioler D, et al. Among authors: kuhrer i. Ann Surg. 2002 Apr;235(4):493-8. doi: 10.1097/00000658-200204000-00006. Ann Surg. 2002. PMID: 11923604 Free PMC article.
23 results